Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

European guideline and expert statements on the management of narcolepsy in adults and children

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Bassetti, CLA, Kallweit, U, Vignatelli, L, Plazzi, G, Lecendreux, M, Baldin, E, Dolenc-Groselj, L, Jennum, P, Khatami, R, Manconi, M, Mayer, G, Partinen, M, Pollmächer, T, Reading, P, Santamaria, J, Sonka, K, Dauvilliers, Y & Lammers, GJ 2021, 'European guideline and expert statements on the management of narcolepsy in adults and children', Journal of Sleep Research, vol. 30, no. 6, e13387, pp. e13387. https://doi.org/10.1111/jsr.13387

APA

Bassetti, C. L. A., Kallweit, U., Vignatelli, L., Plazzi, G., Lecendreux, M., Baldin, E., Dolenc-Groselj, L., Jennum, P., Khatami, R., Manconi, M., Mayer, G., Partinen, M., Pollmächer, T., Reading, P., Santamaria, J., Sonka, K., Dauvilliers, Y., & Lammers, G. J. (2021). European guideline and expert statements on the management of narcolepsy in adults and children. Journal of Sleep Research, 30(6), e13387. [e13387]. https://doi.org/10.1111/jsr.13387

CBE

Bassetti CLA, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, Dolenc-Groselj L, Jennum P, Khatami R, Manconi M, Mayer G, Partinen M, Pollmächer T, Reading P, Santamaria J, Sonka K, Dauvilliers Y, Lammers GJ. 2021. European guideline and expert statements on the management of narcolepsy in adults and children. Journal of Sleep Research. 30(6):e13387. https://doi.org/10.1111/jsr.13387

MLA

Vancouver

Bassetti CLA, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E et al. European guideline and expert statements on the management of narcolepsy in adults and children. Journal of Sleep Research. 2021 Dec;30(6):e13387. e13387. https://doi.org/10.1111/jsr.13387

Author

Bassetti, Claudio L A ; Kallweit, Ulf ; Vignatelli, Luca ; Plazzi, Giuseppe ; Lecendreux, Michel ; Baldin, Elisa ; Dolenc-Groselj, Leja ; Jennum, Poul ; Khatami, Ramin ; Manconi, Mauro ; Mayer, Geert ; Partinen, Markku ; Pollmächer, Thomas ; Reading, Paul ; Santamaria, Joan ; Sonka, Karel ; Dauvilliers, Yves ; Lammers, Gert J. / European guideline and expert statements on the management of narcolepsy in adults and children. In: Journal of Sleep Research. 2021 ; Vol. 30, No. 6. pp. e13387.

Bibtex

@article{b8a234faa3a4467e8088ff5109f87be1,
title = "European guideline and expert statements on the management of narcolepsy in adults and children",
abstract = "BACKGROUND AND PURPOSE: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and children.METHODS: The European Academy of Neurology (EAN), European Sleep Research Society (ESRS), and European Narcolepsy Network (EU-NN) nominated a task force of 18 narcolepsy specialists. According to the EAN recommendations, 10 relevant clinical questions were formulated in PICO format. Following a systematic review of the literature (performed in Fall 2018 and updated in July 2020) recommendations were developed according to the GRADE approach.RESULTS: A total of 10,247 references were evaluated, 308 studies were assessed and 155 finally included. The main recommendations can be summarized as follows: (i) excessive daytime sleepiness (EDS) in adults-scheduled naps, modafinil, pitolisant, sodium oxybate (SXB), solriamfetol (all strong); methylphenidate, amphetamine derivatives (both weak); (ii) cataplexy in adults-SXB, venlafaxine, clomipramine (all strong) and pitolisant (weak); (iii) EDS in children-scheduled naps, SXB (both strong), modafinil, methylphenidate, pitolisant, amphetamine derivatives (all weak); (iv) cataplexy in children-SXB (strong), antidepressants (weak). Treatment choices should be tailored to each patient's symptoms, comorbidities, tolerance and risk of potential drug interactions.CONCLUSION: The management of narcolepsy involves non-pharmacological and pharmacological approaches with an increasing number of symptomatic treatment options for adults and children that have been studied in some detail.",
keywords = "Adult, Cataplexy, Child, Humans, Modafinil/therapeutic use, Narcolepsy/diagnosis, Sleep, Sodium Oxybate/therapeutic use, cataplexy, narcolepsy, European, management, guideline",
author = "Bassetti, {Claudio L A} and Ulf Kallweit and Luca Vignatelli and Giuseppe Plazzi and Michel Lecendreux and Elisa Baldin and Leja Dolenc-Groselj and Poul Jennum and Ramin Khatami and Mauro Manconi and Geert Mayer and Markku Partinen and Thomas Pollm{\"a}cher and Paul Reading and Joan Santamaria and Karel Sonka and Yves Dauvilliers and Lammers, {Gert J}",
note = "{\textcopyright} 2021 The Authors. Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Academy of Neurology and European Sleep Research Society.",
year = "2021",
month = dec,
doi = "10.1111/jsr.13387",
language = "English",
volume = "30",
pages = "e13387",
journal = "Journal of Sleep Research",
issn = "1365-2869",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - European guideline and expert statements on the management of narcolepsy in adults and children

AU - Bassetti, Claudio L A

AU - Kallweit, Ulf

AU - Vignatelli, Luca

AU - Plazzi, Giuseppe

AU - Lecendreux, Michel

AU - Baldin, Elisa

AU - Dolenc-Groselj, Leja

AU - Jennum, Poul

AU - Khatami, Ramin

AU - Manconi, Mauro

AU - Mayer, Geert

AU - Partinen, Markku

AU - Pollmächer, Thomas

AU - Reading, Paul

AU - Santamaria, Joan

AU - Sonka, Karel

AU - Dauvilliers, Yves

AU - Lammers, Gert J

N1 - © 2021 The Authors. Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Academy of Neurology and European Sleep Research Society.

PY - 2021/12

Y1 - 2021/12

N2 - BACKGROUND AND PURPOSE: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and children.METHODS: The European Academy of Neurology (EAN), European Sleep Research Society (ESRS), and European Narcolepsy Network (EU-NN) nominated a task force of 18 narcolepsy specialists. According to the EAN recommendations, 10 relevant clinical questions were formulated in PICO format. Following a systematic review of the literature (performed in Fall 2018 and updated in July 2020) recommendations were developed according to the GRADE approach.RESULTS: A total of 10,247 references were evaluated, 308 studies were assessed and 155 finally included. The main recommendations can be summarized as follows: (i) excessive daytime sleepiness (EDS) in adults-scheduled naps, modafinil, pitolisant, sodium oxybate (SXB), solriamfetol (all strong); methylphenidate, amphetamine derivatives (both weak); (ii) cataplexy in adults-SXB, venlafaxine, clomipramine (all strong) and pitolisant (weak); (iii) EDS in children-scheduled naps, SXB (both strong), modafinil, methylphenidate, pitolisant, amphetamine derivatives (all weak); (iv) cataplexy in children-SXB (strong), antidepressants (weak). Treatment choices should be tailored to each patient's symptoms, comorbidities, tolerance and risk of potential drug interactions.CONCLUSION: The management of narcolepsy involves non-pharmacological and pharmacological approaches with an increasing number of symptomatic treatment options for adults and children that have been studied in some detail.

AB - BACKGROUND AND PURPOSE: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and children.METHODS: The European Academy of Neurology (EAN), European Sleep Research Society (ESRS), and European Narcolepsy Network (EU-NN) nominated a task force of 18 narcolepsy specialists. According to the EAN recommendations, 10 relevant clinical questions were formulated in PICO format. Following a systematic review of the literature (performed in Fall 2018 and updated in July 2020) recommendations were developed according to the GRADE approach.RESULTS: A total of 10,247 references were evaluated, 308 studies were assessed and 155 finally included. The main recommendations can be summarized as follows: (i) excessive daytime sleepiness (EDS) in adults-scheduled naps, modafinil, pitolisant, sodium oxybate (SXB), solriamfetol (all strong); methylphenidate, amphetamine derivatives (both weak); (ii) cataplexy in adults-SXB, venlafaxine, clomipramine (all strong) and pitolisant (weak); (iii) EDS in children-scheduled naps, SXB (both strong), modafinil, methylphenidate, pitolisant, amphetamine derivatives (all weak); (iv) cataplexy in children-SXB (strong), antidepressants (weak). Treatment choices should be tailored to each patient's symptoms, comorbidities, tolerance and risk of potential drug interactions.CONCLUSION: The management of narcolepsy involves non-pharmacological and pharmacological approaches with an increasing number of symptomatic treatment options for adults and children that have been studied in some detail.

KW - Adult

KW - Cataplexy

KW - Child

KW - Humans

KW - Modafinil/therapeutic use

KW - Narcolepsy/diagnosis

KW - Sleep

KW - Sodium Oxybate/therapeutic use

KW - cataplexy

KW - narcolepsy

KW - European

KW - management

KW - guideline

UR - http://www.scopus.com/inward/record.url?scp=85108792524&partnerID=8YFLogxK

U2 - 10.1111/jsr.13387

DO - 10.1111/jsr.13387

M3 - Review

C2 - 34173288

VL - 30

SP - e13387

JO - Journal of Sleep Research

JF - Journal of Sleep Research

SN - 1365-2869

IS - 6

M1 - e13387

ER -

ID: 72158195